Bay Street Bets
Published: 23 June 2026
BioMark prepares to launch its breakthrough liquid biopsy powered by a newly patented algorithm validated in over 15,000 samples across Quebec, France, and Germany. Vancouver, British Columbia–(Newsfile Corp. – June 23, 2026) – BioMark Diagnostics…
Published: 9 June 2026
New patent expands globally protected IP estate beyond blood into alternative biofluids, positioning the Company's clinical mass spectrometry platform against traditional genomic liquid biopsies. Vancouver, British Columbia–(Newsfile Corp. – June 9, 2026) – BioMark Diagnostics…
Published: 14 April 2026
BioMark Comprehensive Metabolomics Assay Selected as Top Canadian Innovation for the CTS Beaver Den Innovation Award Vancouver, British Columbia–(Newsfile Corp. – April 14, 2026) – BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the…
Published: 15 January 2026
Advancing Superior Accuracy in Early Lung Cancer Detection Using Selective Metabolic Pathways and Data Enrichment for Enhanced Diagnostic Capabilities Vancouver, British Columbia–(Newsfile Corp. – January 15, 2026) – BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B)…
Published: 31 December 2025
Celebrating A Year of Extraordinary Achievement Vancouver, British Columbia–(Newsfile Corp. – December 31, 2025) – BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies for early…
Login required
Username or Email Address
Password
Remember Me
You need to log in to add this page to your watchlist.
Username
Register
BSB WATCHLIST
log in
to manage your watchlist.
WSB for Canucks
